How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?
How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Miami Sylvester Comprehensive Cancer Center
Answered on
At Sylvester we have found that patients with GIST whose tumors progress in imatinib often harbor resistance mutations that may be detected by a blood test called “circulating tumor DNA”. There is growing evidence that patients with one type of mutation do much better with sunitinib while a differen...
Join for free or sign in to see the full answer